Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome January 26, 2023
Soleno Therapeutics Announces Financing Commitment for up to $60 Million December 19, 2022
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results November 9, 2022
There are currently no events to display.
Developing novel therapeutics for the treatment of rare diseases.